Immix Biopharma NXC-201 Trial Meets Primary Endpoint With 70% Complete Response in AL Amyloidosis

Immix Biopharma has announced promising interim results from its NXC-201 cell therapy in treating relapsed/refractory AL Amyloidosis, achieving a 70% complete response rate at the 2025 American Society of Clinical Oncology Annual Meeting. The U.S.-based NEXICART-2 clinical trial showed that all treated patients normalized disease markers, with additional improvements in cardiac and renal functions and no relapses or severe safety concerns reported. This outcome is significant compared to conventional treatments, which typically yield less than a 10% complete response rate, highlighting the high unmet medical need. Immix is planning further discussions on these findings during a Key Opinion Leader event scheduled for June 3, 2025, and is advancing toward a Biologics License Application submission for FDA approval. Analysts have expressed optimism, assigning an "Outperform" recommendation with a projected stock price upside exceeding 200%. The results underscore the transformative potential of Immix's cell therapy in a challenging disease area.